Search - tctmd.com

Displaying 1 - 20 of 417

Sort: Relevancy | Date

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

Caitlin E. Cox

November 06, 2025

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Presentation TCT 2025

TCT 1009: Antithrombotic Strategy in Patients With Multivessel or Left Main Coronary Disease: A Post-Hoc Analysis From the EPIC-CAD Trial

Presenter: Kyeong-Won Seo

October 27, 2025

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

Presentation TCT India 2025

STEMI with Complex Left Main Disease

Presenter: J. Ramakrishna

July 27, 2025

News Conference News EuroPCR 2025

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

L.A. McKeown

May 28, 2025

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Conference News EuroPCR 2025

IVL Effective in Severely Calcified Lesions, Especially in Women

Yael L. Maxwell

May 22, 2025

News Conference News EuroPCR 2025

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

Yael L. Maxwell

May 21, 2025

News Daily News

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

Caitlin E. Cox

April 28, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

Advertisement

Beta-blockers Not Helpful After MI in Patients With Preserved EF

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

TCT 1009: Antithrombotic Strategy in Patients With Multivessel or Left Main Coronary Disease: A Post-Hoc Analysis From the EPIC-CAD Trial

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

What’s Going to Be Hot at TCT 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

What’s Going to Be Hot at ESC Congress 2025?

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

STEMI with Complex Left Main Disease

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

IVL Effective in Severely Calcified Lesions, Especially in Women

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content